Orchestra BioMed Holdings Announces Board and Compensation Changes
Ticker: OBIO · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1814114
| Field | Detail |
|---|---|
| Company | Orchestra Biomed Holdings, Inc. (OBIO) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $50 billion, $6 billion, $60 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, governance
TL;DR
Board shakeup and pay plan updates at Orchestra BioMed.
AI Summary
Orchestra BioMed Holdings, Inc. announced on January 30, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about future strategic direction and operational stability.
Key Players & Entities
- Orchestra BioMed Holdings, Inc. (company) — Registrant
- January 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 150 Union Square Drive New Hope, Pennsylvania 18938 (address) — Principal executive office
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates departures of certain officers and directors, but does not specify the exact roles in this summary section.
Who are the newly elected directors?
The filing mentions the election of directors but does not name them in the provided text.
What are the key changes in the compensatory arrangements?
The filing notes updates to compensatory arrangements for certain officers, but the specifics are not detailed here.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is January 30, 2025.
What is the principal executive office address of Orchestra BioMed Holdings, Inc.?
The principal executive office is located at 150 Union Square Drive, New Hope, Pennsylvania 18938.
Filing Stats: 1,091 words · 4 min read · ~4 pages · Grade level 9.8 · Accepted 2025-02-05 08:18:45
Key Financial Figures
- $0.0001 — h registered Common stock, par value $0.0001 per share OBIO The Nasdaq Global Mark
- $50 billion — ate development efforts for Medtronic's $50 billion acquisition of Covidien Group S..r.l. M
- $6 billion — enture investments and orchestrated the $6 billion sale of Covidien Group S..r.l's medical
- $60 billion — closing acquisitions totaling more than $60 billion across over 200 transactions in the Uni
Filing Documents
- tm255461d1_8k.htm (8-K) — 28KB
- tm255461d1_ex99-1.htm (EX-99.1) — 17KB
- 0001104659-25-009393.txt ( ) — 224KB
- obio-20250130.xsd (EX-101.SCH) — 3KB
- obio-20250130_lab.xml (EX-101.LAB) — 33KB
- obio-20250130_pre.xml (EX-101.PRE) — 22KB
- tm255461d1_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On February 5, 2025, the Company issued a press release announcing the appointment of Mr. Cleary and the departure of Mr. Rose from the Board. A copy of the press release is attached to this Current Report on Form 8-K (" Current Report ") as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure. The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated February 5, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORCHESTRA BIOMED HOLDINGS, INC. By: /s/ Andrew Taylor Name: Andrew Taylor Title: Chief Financial Officer Date: February 5, 2025 4